康希诺生物 CanSinoBIO

Keywords you search：

1 CanSinoBIO Initiates Phase Ⅲ Clinical Trial of Group ACYW135 Meningococcal Conjugate Vaccine Menhycia® in Indonesia

Description
2 CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine

Description
3 INSIDE INFORMATION UPDATES ON 2023 PRELIMINARY ANNUAL RESULTS

Description
4 ELECTIONS RELATING TO BOARD OF DIRECTORS, BOARD COMMITTEES AND BOARD OF SUPERVISORS

Description
5 List of Directors and their Roles and Functions

Description
6 VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF DRUG REGISTRATION APPLICATION FOR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (CRM197, TT VECTOR)

Description
7 Monthly Return of Equity Issuer on Movements in Securities

Description
8 NOTICE OF BOARD MEETING

Description
9 VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE III CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR ABSORBED TETANUS VACCINE

Description
10 ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

Description

First Page Pre. Page Current Page(58) Next Page End Page(62)